Table 1.
Cancer patients with chemotherapy-induced peripheral neuropathy (n=88): Demographics and the associations of demographic and cancer-related factors with falls and functional impairments
| Variable | Total, n (%) n = 88 | Any falls, n (%) n = 36 | No fall, n (%) n = 51 | P | Any functional impairment, n (%) n = 29 | No functional impairments, n (%) n = 58 | P |
|---|---|---|---|---|---|---|---|
| Age, years | |||||||
| <65 | 68 (77.3) | 26 (74.3) | 42 (82.4) | 0.424 | 16 (57.1) | 51 (87.9) | 0.002 |
| ≥65 | 19 (21.6) | 9 (25.7) | 9 (17.7) | 12 (42.9) | 7 (12.1) | ||
| Unknown | 1 (1.1) | ||||||
| Educational level | |||||||
| High school or less | 17 (19.3) | 10 (27.8) | 7 (13.7) | 0.169 | 10 (34.5) | 7 (12.1) | 0.021 |
| College or above | 71 (80.7) | 26 (72.2) | 44 (86.3) | 19 (65.5) | 51 (87.9) | ||
| Employment | |||||||
| Employed | 45 (51.1) | 18 (50.0) | 26 (52.0) | >0.999 | 9 (31.0) | 35 (61.4) | 0.012 |
| Nonemployed | 42 (47.7) | 18 (50.0) | 24 (48.0) | 20 (69.0) | 22 (38.6) | ||
| Unknown | 1 (1.1) | ||||||
| Cancer stage | |||||||
| 1/II | 50 (56.8) | 18 (52.9) | 32 (68.1) | 0.247 | 11 (39.3) | 38 (71.7) | 0.008 |
| III/IV | 32 (36.4) | 16 (47.1) | 15 (31.9) | 17 (60.7) | 15 (28.3) | ||
| Unknown | 6 (6.8) | ||||||
| Recurrence/metastasis | |||||||
| Yes | 8 (9.1) | 1 (2.8) | 7 (13.7) | 0.133 | 4 (13.8) | 4 (6.9) | 0.432 |
| No | 80 (90.9) | 35 (97.2) | 44 (86.3) | 25 (86.2) | 54 (93.1) | ||
| Radiation | |||||||
| Yes | 54 (61.4) | 23 (63.9) | 30 (60.0) | 0.823 | 14 (48.3) | 39 (68.4) | 0.100 |
| No | 33 (37.5) | 13 (36.1) | 20 (40.0) | 15 (51.7) | 18 (31.6) | ||
| Duration of chemotherapy administration (months), mean±SD | 6.6±10.2 | 4.9±6.1 | 7.0±11.2 | 0.297 | 8.7±16.1 | 5.6±5.4 | 0.176 |
| Total dose of taxane anticancer agents, mean±SD | 1446.3±1558.8 | 1074.4±512.2 | 1649.1±1927.9 | 0.085 | 1802.7±2442.1 | 1265.4±825.1 | 0.133 |
| Regimen | |||||||
| Docetaxel based | 27 (30.7) | 13 (36.1) | 14 (27.5) | 0.290 | 10 (34.5) | 17 (29.3) | 0.667 |
| Paclitaxel based | 59 (67.0) | 22 (61.1) | 37 (72.6) | 18 (62.1) | 40 (69.0) | ||
| Both DOC + PAC | 2 (2.3) | 1 (2.8) | 0 (0.0) | 1 (3.5) | 1 (1.7) | ||
| NCI-CTCAE version 4.0 CIPN grade | |||||||
| 1 | 71 (80.7) | 26 (72.2) | 45 (88.2) | 0.090 | 17 (58.6) | 53 (91.4) | 0.001 |
| ≥2 | 17 (19.3) | 10 (27.8) | 6 (11.8) | 12 (41.4) | 5 (8.6) | ||
| Total scores of FACT/GOG-NTX, mean±SD | 31.4±9.0 | 28.6±8.6 | 33.5±8.7 | 0.011 | 24.8±8.3 | 34.7±7.5 | <0.001 |
| Level of any functional impairment | |||||||
| Yes (>1) | 29 (33.0) | 16 (45.7) | 12 (23.5) | 0.037 | |||
| No | 58 (65.9) | 19 (54.3) | 39 (76.5) |
CIPN: Chemotherapy-induced peripheral neuropathy, DOC: Docetaxel, PAC: Paclitaxel, NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events, SD: Standard deviation, FACT/GOG-NTX: Functional Assessment of Cancer Therapy-Gynecologic Oncology Group-Neurotoxicity. One participant did not answer to the question related to “fall”, and the other one participant did not answer to the question related to “functional impairment”